Last 48 quarters of trend data · Healthcare · Drug Manufacturers - Specialty & Generic
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
EV/EBITDA has compressed 30.1% YoY to 6.7x, reflecting multiple compression or accelerating EBITDA.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 11.09 | — | — | 3.43 | 4.16 | — | 8.06 | — | 64.54 | — | — | — | 27.89 |
| — | — | — | — | -93.6% | — | — | — | +131.4% | — | — | — | — | |
| P/S Ratio | 0.17 | 0.20 | 0.23 | 0.23 | 0.24 | 0.27 | 0.29 | 0.30 | 0.27 | 0.45 | 0.30 | 0.34 | 0.34 |
| — | -23.8% | -22.6% | -23.7% | -10.1% | -41.3% | -3.7% | -10.8% | -20.8% | +19.4% | +17.4% | +9.7% | -12.0% | |
| P/B Ratio | 4.75 | — | 6.84 | 6.81 | 16.90 | — | — | — | — | — | — | — | 14.36 |
| — | — | — | — | — | — | — | — | — | — | — | — | +19.8% | |
| P/FCF | 1.78 | 6.06 | 1.60 | 1.93 | 3.27 | 6.87 | 1.52 | 2.26 | 2.15 | 7.60 | 2.98 | 3.18 | 4.09 |
| — | -11.8% | +5.4% | -14.7% | +52.4% | -9.6% | -49.0% | -28.9% | -47.5% | +6.4% | +95.4% | — | -80.0% | |
| EV / EBITDA | 6.28 | 6.68 | 5.48 | 5.46 | 7.24 | 9.56 | 6.77 | 9.29 | 8.36 | 10.50 | 8.82 | 19.58 | 6.19 |
| — | -30.1% | -19.1% | -41.2% | -13.4% | -8.9% | -23.2% | -52.5% | +35.0% | -10.1% | -80.5% | +95.2% | -48.0% | |
| EV / EBIT | 9.75 | 10.47 | 7.69 | 7.79 | 12.10 | 19.55 | 9.86 | 10.93 | 13.88 | 21.10 | 12.02 | 12.49 | 11.82 |
| — | -46.5% | -22.0% | -28.7% | -12.8% | -7.3% | -17.9% | -12.4% | +17.4% | -17.0% | -8.5% | -18.7% | -44.1% |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
Bausch Health Companies Inc.'s operating margin was 20.6% in Q1 2026, down 5.1 pp QoQ and up 7.7 pp YoY. This marks the 3rd consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 22.8% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin expanded 6.2% YoY, indicating pricing power or improving input costs.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 60.9% | 61.2% | 63.0% | 62.6% | 59.7% | 57.6% | 71.6% | 72.3% | 70.1% | 70.3% | 70.7% | 72.2% | 70.1% |
| — | +6.2% | -12.0% | -13.4% | -14.8% | -18.0% | +1.2% | +0.2% | +0.0% | +0.3% | +0.6% | +1.0% | -0.9% | |
| Operating Margin | 21.3% | 20.6% | 25.7% | 26.7% | 18.1% | 12.9% | 21.8% | 12.7% | 16.2% | 13.1% | 15.0% | 0.6% | 19.0% |
| — | +59.7% | +17.9% | +111.1% | +11.6% | -1.0% | +45.0% | +1925.1% | -14.9% | +45.0% | +239.7% | -94.8% | +132.3% | |
| Net Margin | 1.5% | -56.4% | -4.0% | 6.7% | 5.8% | -2.6% | 3.6% | -3.4% | 0.4% | -3.0% | -1.6% | -16.9% | 1.2% |
| — | -2095.9% | -210.2% | +297.2% | +1305.9% | +13.2% | +324.4% | +79.9% | -65.3% | +71.4% | +91.3% | -186.6% | +116.3% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 588.2% | — | -31.1% | 70.4% | 102.4% | — | — | — | — | — | — | — | 14.9% |
| — | — | — | — | — | — | — | — | — | — | — | — | +105.7% | |
| ROA | 0.6% | -5.5% | -0.4% | 0.7% | 0.6% | -0.2% | 0.4% | -0.3% | 0.0% | -0.2% | -0.1% | -1.6% | 0.1% |
| — | -2428.8% | -222.2% | +304.3% | +1399.5% | +7.0% | +344.6% | +80.4% | -67.8% | +70.1% | +90.9% | -211.4% | +123.0% | |
| ROIC | 8.2% | 2.0% | 2.7% | 2.6% | 1.7% | 1.1% | 2.1% | 1.2% | 1.4% | 1.0% | 1.3% | 0.1% | 1.7% |
| — | +83.7% | +32.0% | +129.5% | +24.6% | +9.5% | +62.2% | +1915.0% | -20.1% | +53.8% | +249.2% | -93.3% | +210.8% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
Bausch Health Companies Inc.'s Debt/EBITDA ratio is 25.8x, up from 20.7x last quarter — elevated, raising questions about debt serviceability.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 56.36 | — | 56.36 | 59.11 | 147.88 | — | — | — | — | — | — | — | 75.84 |
| — | — | — | — | — | — | — | — | — | — | — | — | -12.0% | |
| Debt / EBITDA | 6.14 | 25.84 | 20.70 | 20.78 | 27.97 | 36.14 | 24.99 | 33.60 | 30.64 | 36.73 | 32.40 | 71.21 | 21.34 |
| — | -28.5% | -17.2% | -38.2% | -8.7% | -1.6% | -22.9% | -52.8% | +43.6% | -12.1% | -80.7% | +94.3% | -50.3% | |
| Current Ratio | 1.47 | 1.32 | 1.47 | 1.30 | 1.31 | 1.35 | 0.86 | 1.19 | 1.19 | 1.22 | 1.30 | 1.20 | 1.12 |
| — | -2.0% | +72.2% | +9.8% | +9.8% | +9.9% | -34.3% | -0.6% | +6.1% | +13.4% | +20.7% | +14.2% | +3.7% | |
| Quick Ratio | 1.08 | 0.97 | 1.08 | 0.97 | 0.98 | 0.97 | 0.62 | 0.82 | 0.82 | 0.85 | 0.94 | 0.89 | 0.81 |
| — | -0.2% | +75.0% | +18.3% | +18.6% | +13.4% | -34.3% | -8.2% | +1.5% | +11.1% | +17.6% | +15.9% | -6.6% | |
| Interest Coverage | 1.35 | 1.30 | 1.80 | 1.73 | 0.98 | 0.88 | 1.76 | 1.57 | 1.22 | 0.84 | 1.40 | 1.46 | 1.19 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 48 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BHC stock.
Bausch Health Companies Inc.'s current P/E is 11.1x. The average P/E over the last 2 quarters is 3.8x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
Bausch Health Companies Inc.'s current operating margin is 21.3%. Margins have been expanding over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking Bausch Health Companies Inc.'s business trajectory between earnings reports.